Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Endometriosis

Experience with Aromatase Inhibitors

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Current treatment of endometriosis is mainly based on surgery and ovarian suppressive agents. In the last 10 years, it has been demonstrated that aromatase P450, a key enzyme for estrogen biosynthesis, may have a pathogenic role in endometriosis because it is aberrantly expressed in endometriotic implants and in eutopic endometrium of women with endometriosis. Therefore, inhibition of aromatase activity may represent a new therapeutic option for endometriosis. Case reports and observational studies have shown that pain symptoms caused by endometriosis quickly improve after administration of aromatase inhibitors. Limited data are available on the long-term course of pain symptoms after completion of treatment with aromatase inhibitors; however, some recent studies suggest that symptoms may recur at short-term follow-up. A range of results are reported on the effects of aromatase inhibitors on endometriotic lesions, with some authors describing improvements and other authors reporting persistence of pelvic lesions at second-look laparoscopy after treatment. No severe adverse effect has been reported during treatment with aromatase inhibitors both in pre- and post-menopausal women. On the basis of the available data, administration of aromatase inhibitors should now be offered only to the small number of women who have severe pain despite previous surgical and hormonal therapies. Further research in the form of randomized controlled trials will be required before recommending the routine use of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005 Oct; 20(10): 2698–704

    Article  PubMed  Google Scholar 

  2. Guo SW, Wang Y. Sources of heterogeneities in estimating the prevalence of endometriosis in infertile and previously fertile women. Fertil Steril 2006 Dec; 86(6): 1584–95

    Article  PubMed  Google Scholar 

  3. Guo SW, Wang Y. The prevalence of endometriosis in women with chronic pelvic pain. Gynecol Obstet Invest 2006; 62(3): 121–30

    Article  PubMed  Google Scholar 

  4. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obst Gynecol 1927; 14: 442–69

    Google Scholar 

  5. Halme J, Hammond MG, Hulka JF, et al. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 1984 Aug; 64(2): 151–4

    PubMed  CAS  Google Scholar 

  6. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 2002 Feb; 123(2): 217–26

    Article  PubMed  CAS  Google Scholar 

  7. Capellino S, Montagna P, Villaggio B, et al. Role of estrogens in inflammatory response: expression of estrogen receptors in peritoneal fluid macrophages from endometriosis. Ann N Y Acad Sci 2006 Jun; 1069: 263–7

    Article  PubMed  CAS  Google Scholar 

  8. Montagna P, Capellino S, Villaggio B, et al. Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril 2008 Jul; 90(1): 156–64

    Article  PubMed  CAS  Google Scholar 

  9. Hornstein MD, Hemmings R, Yuzpe AA, et al. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997 Nov; 68(5): 860–4

    Article  PubMed  CAS  Google Scholar 

  10. Busacca M, Chiaffarino F, Candiani M, et al. Determinants of long-term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol 2006 Aug; 195(2): 426–32

    Article  PubMed  Google Scholar 

  11. Shakiba K, Bena JF, McGill KM, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008 Jun; 111(6): 1285–92

    Article  PubMed  Google Scholar 

  12. Muzii L, Marana R, Caruana P, et al. Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. Am J Obstet Gynecol 2000 Sep; 183(3): 588–92

    Article  PubMed  CAS  Google Scholar 

  13. Vercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008 May; 198(5): 504 e1-5

    Article  PubMed  CAS  Google Scholar 

  14. Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005; (4): CD004753

  15. Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988 Sep; 72(3 Pt 1): 323–7

    PubMed  CAS  Google Scholar 

  16. Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996 Aug; 175(2): 396–401

    Article  PubMed  CAS  Google Scholar 

  17. Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006 Jan; 21(1): 248–56

    Article  PubMed  CAS  Google Scholar 

  18. Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001 Mar; 75(3): 485–8

    Article  PubMed  CAS  Google Scholar 

  19. Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005 Jul; 20(7): 1993–8

    Article  PubMed  CAS  Google Scholar 

  20. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril 1990 Sep; 54(3): 419–27

    CAS  Google Scholar 

  21. Bergqvist A, Bergh T, Hogstrom L, et al. Effects of tripto-relin versus placebo on the symptoms of endometriosis. Fertil Steril 1998 Apr; 69(4): 702–8

    Article  PubMed  CAS  Google Scholar 

  22. Ferrero S, Abbamonte LH, Anserini P, et al. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv 2005 Dec; 60(12): 817–26

    Article  PubMed  Google Scholar 

  23. Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol 2006 Sep; 149(2): 133–5

    Article  PubMed  CAS  Google Scholar 

  24. Baxendale PM, Reed MJ, James VH. Inability of human endometrium or myometrium to aromatize androstene-dione. J Steroid Biochem 1981 Mar; 14(3): 305–6

    Article  PubMed  CAS  Google Scholar 

  25. Bulun SE, Mahendroo MS, Simpson ER. Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua. J Clin Endocrinol Metab 1993 Jun; 76(6): 1458–63

    Article  PubMed  CAS  Google Scholar 

  26. Noble LS, Simpson ER, Johns A, et al. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996 Jan; 81(1): 174–9

    Article  PubMed  CAS  Google Scholar 

  27. Kitawaki J, Noguchi T, Amatsu T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997 Sep; 57(3): 514–9

    Article  PubMed  CAS  Google Scholar 

  28. Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997 Feb; 82(2): 600–6

    Article  PubMed  CAS  Google Scholar 

  29. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999 Mar; 6(1): 75–92

    Article  PubMed  CAS  Google Scholar 

  30. Takayama K, Zeitoun K, Gunby RT, et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998 Apr; 69(4): 709–13

    Article  PubMed  CAS  Google Scholar 

  31. Razzi S, Fava A, Sartini A, et al. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovari-ectomised woman. BJOG 2004 Feb; 111(2): 182–4

    Article  PubMed  Google Scholar 

  32. Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004 Feb; 81(2): 290–6

    Article  PubMed  CAS  Google Scholar 

  33. Shippen ER, West Jr WJ. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004 May; 81(5): 1395–8

    Article  PubMed  Google Scholar 

  34. Fatemi HM, Al-Turki HA, Papanikolaou EG, et al. Successful treatment of an aggressive recurrent postmenopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online 2005 Oct; 11(4): 455–7

    Article  PubMed  CAS  Google Scholar 

  35. Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005 Aug; 84(2): 300–4

    Article  PubMed  CAS  Google Scholar 

  36. Hefler LA, Grimm C, van Trotsenburg M, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril 2005 Oct; 84(4): 1033–6

    Article  PubMed  CAS  Google Scholar 

  37. Remorgida V, Abbamonte HL, Ragni N, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril 2007 Sep; 88(3): 724–6

    Article  PubMed  CAS  Google Scholar 

  38. Remorgida V, Abbamonte LH, Ragni N, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol 2007 Jun; 47(3): 222–5

    Article  PubMed  Google Scholar 

  39. Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007 Jun; 109(6): 1421–3

    Article  PubMed  Google Scholar 

  40. Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008 Nov; 90(5): 2004 e7-9

    Article  PubMed  Google Scholar 

  41. Takayama K, Zeitoun K, Carr BR, et al. Medical versus surgical treatment of endometriosis? Reply to authors. Fertil Steril 1998; 70(6): 1183–4

    Google Scholar 

  42. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004 Jan; 19(1): 160–7

    Article  PubMed  Google Scholar 

  43. Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008 Jun; 115(7): 818–22

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Prof. Ezio Flucheri for providing the histological images used in the study. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, San Martino Hospital and University of Genoa, Largo R. Benzi 1, 16132, Genoa, Italy

    Simone Ferrero, Nicola Ragni & Valentino Remorgida

  2. Department of Obstetrics and Gynecology, G. Gaslini Institute, Genoa, Italy

    Pier L. Venturini

  3. Department of Surgery, San Martino Hospital and University of Genoa, Genoa, Italy

    Giovanni Camerini

Authors
  1. Simone Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pier L. Venturini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicola Ragni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giovanni Camerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valentino Remorgida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Ferrero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrero, S., Venturini, P.L., Ragni, N. et al. Pharmacological Treatment of Endometriosis. Drugs 69, 943–952 (2009). https://doi.org/10.2165/00003495-200969080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969080-00001

Keywords

Search

Navigation